Table 1 The Demographics and clinical characteristics of the patients being studied

Age-years

68.2 (64.9–71.5)

64.8 (56.5–73.1)

0.814

Sex-female/male-no.

68/73

503/543

0.975

Smoking -Y/N-no.

81/60

418/628

<0.001

Smoking index -pack-year

47.5 (36.2–56.4)

31.8 (22.2–40.1)

0.025

 Adenocarcinoma

125 (88.7)

938 (89.7)

0.279

 Squamous

12 (8.5)

80 (7.6)

0.719

 Other

4 (2.8)

28 (2.7)

0.912

 Stage I

5 (3.5)

231 (22.1)

<0.001

 Stage II

26 (18.4)

260 (24.9)

0.094

 Stage III

42 (29.8)

303 (29.0)

0.841

 Stage IV

68 (48.3)

252 (24.0)

<0.001

 Low

21 (14.9)

632 (60.4)

<0.001

 Moderate

45 (31.9)

253 (24.2)

0.047

 High

75 (53.2)

94 (15.4)

<0.001

Concomitant DVT- no. (%)

45 (31.9)

52 (5.0)

<0.001

D-dimer- ng/ml

4680 (2440–6920)

808 (678–938)

<0.001

Molecular tests-P/N-no.

81/60

552/494

0.296

ALK (+) - no. (%)

11 (13.6%)

47 (8.5%)

<0.001

ROS-1(+) - no. (%)

5 (6.2%)

37 (6.7%)

0.858

EGFR (+) - no. (%)

42 (51.8%)

335 (60.7%)

0.130

BRAF- V600E (+) - no. (%)

3 (3.7%)

23 (4.2%)

0.845

PDL-1(+) (≥1%) - no. (%)

20 (24.7%)

110 (19.9%)

0.001